2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Abstract

Breast cancer is a leading cause of cancer-related morbidity and mortality among women worldwide, characterized by its heterogeneous nature and complex biological behaviors. The advent of targeted therapies has underscored the necessity for deeper insights into the molecular underpinnings of breast cancer. This study focuses on the role of long intergenic non-coding RNAs (lincRNAs), specifically BC7, and their interaction with the breast cancer susceptibility gene BRCA1, particularly in the context of treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor. The research aims to elucidate the signalling pathways and molecular mechanisms by which BC7 modulates BRCA1 function, thereby influencing cellular responses to therapeutic interventions.

The primary objective of this research is to investigate the regulatory mechanisms of BC7 and BRCA1 in triple-negative breast cancer (TNBC) cell lines and human embryonic kidney cells. Employing a combination of experimental methodologies, this study comprehensively evaluates how BC7 affects BRCA1 expression and function in response to PARP inhibitor treatment. Additionally, in silico bioinformatics analyses are utilized to map out the biological pathways influenced by BC7 and identify potential molecular interactions contributing to breast cancer pathogenesis.

Preliminary findings indicate that BC7 significantly influences the expression levels of BRCA1 in breast cancer cells treated with Olaparib. The results suggest that BC7 may act as a critical regulator of BRCA1 signaling pathways, potentially modulating the cellular response to PARP inhibition. This interaction enhances our understanding of breast cancer's molecular landscape and highlights the therapeutic potential of targeting lincRNAs in conjunction with existing treatment modalities.

The implications of this research extend beyond basic science; they offer promising avenues for developing novel therapeutic strategies to overcome drug resistance in breast cancer. By identifying BC7 as a key player in BRCA1-mediated signaling, this study paves the way for future investigations into targeted therapies that could enhance treatment efficacy for patients suffering from aggressive forms of breast cancer. 

In conclusion, this research underscores the importance of non-coding RNAs in cancer biology and their potential role as biomarkers or therapeutic targets in breast cancer management. As we continue to unravel the complexities of breast cancer at the molecular level, studies like this are crucial for advancing our understanding and improving clinical outcomes for patients affected by this devastating disease. Through further exploration of BC7’s interactions with BRCA1 and its implications for treatment response, we aspire to contribute significantly to the evolving landscape of breast cancer research and therapy.

Keywords: breast cancer, BC7, lincRNA, BRCA1, PARP inhibitor.